| Literature DB >> 25880549 |
Yan Zhang1, Yong-Fei Wang2, Jing Yang3, Jing Zhang4, Liangdan Sun5, Nattiya Hirankarn6, Hai-Feng Pan7, Chak Sing Lau8, Tak Mao Chan9, Tsz Leung Lee10, Alexander Moon Ho Leung11, Chi Chiu Mok12, Lu Zhang13, Jiangshan Jane Shen14, Sik Nin Wong15, Ka Wing Lee16, Marco Hok Kung Ho17, Pamela Pui Wah Lee18, Brian Hon-Yin Chung19, Chun Yin Chong20, Raymond Woon Sing Wong21, Mo Yin Mok22, Wilfred Hing Sang Wong23, Kwok Lung Tong24, Niko Kei Chiu Tse25, Xiang-Pei Li26, Yingyos Avihingsanon27, Pornpimol Rianthavorn28, Thavatchai Deekajorndej29, Kanya Suphapeetiporn30, Vorasuk Shotelersuk31, Shirley King Yee Ying32, Samuel Ka Shun Fung33, Wai Ming Lai34, Chun-Ming Wong35, Irene Oi Lin Ng36, Maria-Merce Garcia-Barcelo37, Stacey S Cherny38, Paul Kwong-Hang Tam39, Pak Chung Sham40,41, Sen Yang42, Dong Qing Ye43, Yong Cui44, Xue-Jun Zhang45, Wanling Yang46,47, Yu Lung Lau48.
Abstract
INTRODUCTION: Systemic lupus erythematosus (SLE) is a heterogeneous disease with a diverse spectrum of clinical symptoms, ranging from skin rash to end-organ damage. 22q11.21 has been identified as a susceptibility region for several autoimmune diseases, including SLE. However, detailed information for SLE association and the underlying functional mechanism(s) is still lacking.Entities:
Mesh:
Year: 2015 PMID: 25880549 PMCID: PMC4404227 DOI: 10.1186/s13075-015-0577-6
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Association results of single-nucleotide polymorphism rs2298428 from each cohort and joint analysis
|
|
|
|
|
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| rs2298428 |
| 0.50 | 0.46 | 1.71E-03 | 1.17 | 0.44 | 0.37 | 3.16E-09 | 1.29 | 0.49 | 0.45 | 0.06 | 1.16 | 1.31E-11 | 1.23 (1.16 to 1.30) | 0.26 |
aAA, Amino acid; AH, Anhui; AH_GWAS + AH_REP, Cases from Anhui were patients visiting the Department of Rheumatology at Anhui Provincial Hospital and the First Affiliated Hospital of Anhui Medical University in Hefei, Anhui province (AH_REP), with corresponding controls from healthy blood donors in Anhui (AH_REP). The cases for the Anhui GWAS (AH_GWAS) were recruited from several hospitals in central and southern China, and the controls were carefully selected with geographically matched and clinically unrelated individuals (AH_GWAS); GWAS, Genome-wide association studies; HK, Hong Kong; HK_GWAS + HK_REP, Cases from five hospitals in Hong Kong: Queen Mary Hospital, Tuen Mun Hospital, Queen Elizabeth Hospital, Pamela Youde Nethersole Eastern Hospital and Princess Margaret Hospital; TH_REP, Cases from Thailand were patients at King Chulalongkorn Memorial Hospital. F_A/F_U indicates minor allele frequency of the single-nucleotide polymorphism (SNP) in cases or controls. The calculation of odds ratio (OR) is also based on the minor allele of each SNP.
Meta-analysis results for single-nucleotide polymorphisms reported in previous genome-wide association studies on other immune-related diseases in the 22q11.21 region
|
|
|
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
| G | rs463426 | 21,809,185 | C/ | 0.46/0.53 | 3.62E-05 | 0.78 (0.70 to 0.88) | 0.42/0.45 | 0.08 | 0.89 (0.79 to 1.02) | 2.50E-05 | 0.14 | SLE |
| G | rs131654 | 21,917,190 | G/ | 0.41/0.48 | 1.60E-05 | 0.77 (0.69 to 0.87) | 0.38/0.40 | 0.24 | 0.93 (0.81 to 1.05) | 7.27E-05 | 0.04 | SLE |
| I | rs2266959 | 21,922,904 |
| 0.45/0.37 | 3.22E-07 | 1.37 (1.21 to 1.54) | 0.52/0.47 | 1.66E-03 | 1.22 (1.07 to 1.38) | 4.41E-09 | 0.27 | IBD |
| I | rs181359 | 21,928,641 |
| 0.53/0.46 | 1.86E-06 | 1.33 (1.18 to 1.50) | 0.58/0.56 | 0.07 | 1.12 (0.99 to 1.28) | 2.36E-06 | 0.06 | PS, CD |
| G | rs5754217 | 21,939,675 |
| 0.53/0.46 | 1.04E-06 | 1.34 (1.19 to 1.51) | 0.59/0.56 | 0.09 | 1.12 (0.98 to 1.27) | 2.07E-06 | 0.04 | SLE |
| G | rs2298428 | 21,982,892 |
| 0.44/0.37 | 4.72E-07 | 1.37 (1.21 to 1.54) | 0.51/0.46 | 8.44E-04 | 1.24 (1.09 to 1.40) | 2.70E-09 | 0.36 | CD, CeD, RA, SSc |
aAH, Anhui; CeD, Celiac disease; CS, Crohn’s disease; CI, Confidence interval; HK, Hong Kong; IBD, Inflammatory bowel disease; PS, Psoriasis; RA, Rheumatoid arthritis; SSc, Systemic sclerosis; SLE, Systemic lupus erythematosus. G/I indicates whether the single-nucleotide polymorphism (SNP) are genotyped (G) or imputed (I). A1/A2 indicates the minor allele/major allele of the SNP. F_A/F_U indicates minor allele frequency of the SNP in cases or controls. The calculation of odds ratio (OR) is also based on the minor allele of each SNP. The risk allele of each SNP is italics.
Figure 1The linkage disequilibrium patterns of the susceptibility single-nucleotide polymorphisms for autoimmune diseases in different populations. AH, Anhui; CeD, Celiac disease; CEU, Utah residents with ancestry from northern and western Europe; CHB, Han Chinese, Beijing; HK, Hong Kong; IBD, Inflammatory bowel disease; PS, Psoriasis; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus.
Independent effects among the single-nucleotide polymorphisms in the 22q11.21 region
|
|
|
|
|---|---|---|
| rs463426 | 0.76 | – |
| rs131654 | 0.47 | – |
| rs2266959 | 0.46 | – |
| rs181359 | 0.31 | – |
| rs5754217 | 0.36 | – |
| rs2298428 | 2.48E-08 | 1.29 (1.18 to 1.41) |
aCI, Confidence interval; OR, Odds ratio; SNP, Single-nucleotide polymorphism.
Conditional logistic regression analysis
|
| |||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| rs463426 | OR (95% CI) | 1.14 (1.01 to 1.27) | 1.02 (0.91 to 1.14) | 1.1 (0.98 to 1.23) | 1.09 (0.98 to 1.23) | 1.05 (0.94 to 1.17) | |
|
|
| 0.74 | 0.12 | 0.12 | 0.39 | ||
| rs131654 | OR (95% CI) | 1.10 (0.98 to 1.24) | 0.95 (0.82 to 1.10) | 0.99 (0.81 to 1.21) | 0.94 (0.77 to 1.15) | 0.96 (0.85 to 1.10) | |
|
| 0.09 | 0.51 | 0.92 | 0.57 | 0.59 | ||
| rs2266959 | OR (95% CI) | 1.27 (1.14 to 1.43) | 1.33 (1.16 to 1.53) | 1.37 (1.15 to 1.63) | 1.36 (1.14 to 1.62) | 0.79 (0.43 to 1.45) | |
|
|
|
|
|
| 0.44 | ||
| rs181359 | OR (95% CI) | 1.16 (1.04 to 1.30) | 1.25 (1.03 to 1.52) | 0.92 (0.77 to 1.11) | 0.17 (0.01 to 3.89) | 0.98 (0.83 to 1.14) | |
|
| 8.88E-03 |
| 0.39 | 0.27 | 0.76 | ||
| rs5754217 | OR (95% CI) | 1.17 (1.04 to 1.31) | 1.3 (1.08 to 1.57) | 0.93 (0.77 to 1.11) | 0.94 (0.77 to 1.11) | 0.98 (0.84 to 1.14) | |
|
|
|
| 0.41 | 0.20 | 0.79 | ||
| rs2298428 | OR (95% CI) | 1.27 (1.14 to 1.41) | 1.33 (1.18 to 1.51) | 1.61 (0.87 to 2.95) | 1.31 (1.13 to 1.53) | 1.32 (1.13 to 1.53) | |
|
|
|
| 0.13 |
|
| ||
aCI, Confidence interval; OR, Odds ratio; SNP, Single-nucleotide polymorphism. Independence tests were performed using the two genome-wide association datasets. Conditional P-values <0.05 are shown in bold.
Figure 2Association -values of all single-nucleotide polymorphisms before and after adjustment for the effect of rs2298428. The graph depicts the association P -values of all single-nucleotide polymorphisms (SNPs) before (the gradient colors of dots reflects the linkage disequilibrium (LD) between the SNPs and SNP rs2298428, using hg19/1000 Genomes March 2012 ASN (Asian) as a reference) and after (gray) adjustment for the effect of rs2298428. The arrows show the reduction of the SNPs after the association adjusted by the effect of rs2298428.
The expression quantitative trait loci evidence on the single-nucleotide polymorphism rs2298428 on systemic lupus erythematosus and other immune-related diseases
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
| |||
| rs2298428 | 0.0012 | 0.0136 | 0.0158 | 9.4E-06 | – | 0.0047 | – | – | 1.3E-05 | 9.6E-15 |
aAH, Anhui; CEU, Utah residents with ancestry from northern and western Europe; CHB, Han Chinese in Bejing, China; GIH, Gujarati Indian from Houston, Texas;JPT,Japanese in Tokyo, Japan; LWK,Luhya in Webuye, Kenya; MEX,Mexican ancestry in Los Angeles, California; MKK,Maasai in Kinyawa, Kenya; YRI,Yoruba in Ibadan, Nigeria; LCL, Lymphoblastoid cell line; SNP, Single-nucleotide polymorphism.